Ultrasound Trial Tests Chemo Boost for Pancreatic Cancer
Patients with borderline resectable or locally advanced pancreatic cancer are being enrolled in a trial combining focused ultrasound with chemotherapy.
Updated on Nov. 7, 2026 in Cancer

IMGT, a medical device company focused on therapeutic focused ultrasound, has completed first patient enrollment for its SonoPAN III confirmatory trial at the University of Virginia. The randomized study will involve 366 people in South Korea and the U.S. with borderline resectable or locally advanced pancreatic cancer.
Why it matters
Pancreatic cancer is often diagnosed at an advanced stage, and the trial tests whether adding focused ultrasound to standard chemotherapy can improve overall survival for patients in that group. The study is designed to verify results from an earlier small South Korean trial before the company seeks U.S. FDA approval.
The confirmatory SonoPAN III study is a randomized trial of 366 patients with borderline resectable or locally advanced pancreatic cancer, with overall survival as its primary endpoint. It follows a 30-person randomized exploratory trial at Seoul National University Hospital, and its results are not yet available.
The players
IMGT
A medical device company specializing in therapeutic focused ultrasound, sponsoring the SonoPAN III trial and the IMD10 device.
University of Virginia
A U.S. academic medical center serving as the site of first patient enrollment in the SonoPAN III trial.
Seoul National University Hospital
A leading South Korean hospital that conducted IMGT's exploratory trial and will take part in the South Korean portion of the study.
Brigham and Women's Hospital
A Boston-based hospital affiliated with Harvard Medical School, participating as a U.S. trial site.
Mayo Clinic
A nonprofit academic medical center known for cancer care and research, participating as a U.S. trial site.
The details
IMD10 uses focused ultrasound to create microbubbles that temporarily increase the permeability of cell membranes. The device is intended to help anticancer drugs move more effectively into tumors. In the trial, one arm receives FOLFIRINOX chemotherapy alone and the other receives FOLFIRINOX together with the IMD10 device.
Timeline
November 5, 2026: IMGT announced completion of first patient enrollment for the SonoPAN III trial at the University of Virginia.
Health Landscape
Pancreatic cancer remains among the cancers with the lowest survival rates, and most patients are diagnosed when surgery is no longer an option. Trials like SonoPAN III test whether adding localized treatments to chemotherapy can extend survival in this population.
Patients with borderline resectable or locally advanced pancreatic cancer may wish to ask their oncologist whether clinical trials, including ones combining focused ultrasound with chemotherapy, are an option. Results from this trial will not be available for some time, so current standard treatment decisions remain the primary focus.
The takeaway
Localized ultrasound therapy is being tested as a way to help chemotherapy reach pancreatic tumors, but its benefit is unproven until the confirmatory trial reports overall survival results. Patients interested in trial participation should discuss eligibility with their oncology team.
Further reading
For broader context on treatment approaches, explore our Cancer coverage.
Source note: This article includes information reported by 조선일보.





